A Phase 2 interventional study of VIT-2763 once a day (QD) and VIT-2763 twice a day (BID) in Beta-Thalassemia and Non-transfusion-dependent Thalassemia, sponsored by Vifor (International) Inc.. Completed at 16 sites in 5 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in beta-Thalassemia with a site in Italy — 8 open to participants now, 17 under way, 6 of them phase 3. beta-Thalassemia · Italy.
Among the 49 studies in beta-Thalassemia with a site in Italy, this one is the 25th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2020, is one of 18 in phase 2, and was the 36th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →8 of the 49 studies in beta-Thalassemia with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Telethon · Sites in Italy
Ages 3–35
Cyprus Institute of Neurology and Genetics · Sites in Italy, United States, Angola and 13 more countries
Ages 2+
Vertex Pharmaceuticals Incorporated · Sites in Italy, United States, Germany and 1 more country
Ages 12–35
Celgene · Sites in Italy, United States, China and 6 more countries
Ages 6–17
Celgene · Sites in Italy, United States, Australia and 19 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 21 · Phase 3 13 · Phase 4 4
First in 2000; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 55 across the 39 interventional studies, 120 across the 10 observational. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Vifor (International) Inc., one of the names counted as CSL Limited. Under that name alone:
Vifor (International) Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
CSL Limited has 2 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
5 of the studies in beta-Thalassemia with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
| NCT01639690San Rocco Therapeuticsß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene | 2027-07 |
| NCT05799118Cyprus Institute of Neurology and GeneticsStudy of the Role of Genetic Modifiers in Hemoglobinopathies | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 49 studies in beta-Thalassemia with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomised, double-blind, placebo-controlled parallel group trial to investigate the safety, tolerability and efficacy of multiple doses of VIT-2763 versus placebo in participants with non-transfusion-dependent Beta-thalassemia (NTDT).
The study includes a 12-week treatment period and a safety follow-up period of 4 weeks.
About 36 participants (adults and adolescents) are expected to take part in this study at a number of different institutions internationally.
Adult Participants (Cohort I) will be randomized to receive either VIT-2763 once daily (QD) or twice daily (BID) or placebo, at a dose of 120 mg or 60mg depending on their body weight. Following cohort I review, adolescent participants (Cohort II) will be randomized to the same study arms with the same interventions.
The study medication will be given as oral capsules, containing 60 mg of VIT-2763 or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be assigned to receive VIT-2763 once a day (QD) in a total daily dose of 60 mg or 120 mg depending on their body weight. The study medication (VIT-2763 and/or matching placebo) will be administered for all participants twice a day to maintain the blind.
Drug: VIT-2763 once a day (QD)
Participants will be assigned to receive VIT-2763 Twice a day (BID) in a total daily dose of 60 mg or 120 mg depending on their body weight.
Drug: VIT-2763 twice a day (BID)
Participants will be assigned to receive Placebo, Twice a day.
Drug: Placebo
Participants will receive VIT-2763 QD at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Participants will receive VIT-2763 BID at a dose of 60 mg if their body weight is between 40 kg to 59 kg or at a dose of 120 mg if their body weight is between 60 kg and 100 kg, during 12 weeks.
Participants will receive hard capsules of Placebo, twice a day.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participants, in particular, the number of participants with at least one TEAE. Please refer to the detailed tables included on the Adverse Event Module for specifics.
Time frame: From baseline to Week 16
Changes in the Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Summary of the values by visit from baseline and changes from baseline by post-baseline visit.
Time frame: From baseline to Week 12
Changes in the Heart Rate
Summary of the values by visit from baseline and changes from baseline by post-baseline visit.
Time frame: From baseline to Week 12
Changes in 12-lead Electrocardiogram (ECG) Parameters
Values by visit from baseline and changes from baseline by post-baseline visit. The following ECG parameters were recorded: PR interval, QRS duration, QT interval, RR interval and QTcF interval. PR interval represents the time from the onset of the P wave to the start of the QRS complex. QRS duration represents the time required for a stimulus to spread through the ventricles (ventricular depolarization). QT interval represents the time from the start of the Q wave to the end of the T wave. RR interval represents the time from the onset of one R wave to the onset of the next one, one complete cardiac cycle. QT corrected for heart rate (QTc) interval reflects ventricular repolarization.
Time frame: From baseline to Week 12
Change From Baseline in Total Serum Iron
Assessment of total serum Iron from baseline over a 12-week period (absolute and change from baseline). For the serum iron parameter, the 'Baseline' was collected during the screening period within the biochemistry sample.
Time frame: From baseline to Week 12
Change From Baseline in Serum Ferritin
Assessment of serum ferritin from baseline over a 12-week period (absolute and change from baseline). For the serum ferritin parameter, the 'Baseline' was collected during the screening period within the biochemistry sample.
Time frame: From baseline to Week 12
Change From Baseline in Serum Transferrin
Assessment of serum transferrin from baseline over a 12-week period (absolute and change from baseline). For the serum transferrin parameter, the "Baseline 2h post-dose" was defined as the value at Visit 3 2h post-dose.
Time frame: From baseline to Week 12
Change From Baseline in Calculated Transferrin Saturation (TSAT) )
Assessment of TSAT from baseline over a 12-week period (absolute and change from baseline). For the calculated transferrin saturation parameter, the 'Baseline' was collected during the screening period within the biochemistry sample. Transferrin Saturation (TSAT) was calculated as Total Iron /Total Iron Binding Capacity (TIBC) X 100.
Time frame: From baseline to Week 12
Pharmacokinetics Parameters - VIT-2763 Plasma Concentration Over Time
Sparse sampling for determination of VIT-2763 plasma concentration following multiple dosing was obtained from pre-dose trough to 3 hours or 4 hours post-dose at selected study visits. Pharmacokinetics parameters (Cmax, clearance, distribution volume, area under the curve (AUC) were not calculated for the study.
Time frame: Baseline, Week 4, Week 8 and Week 12
| Milestone | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Started | 9 | 12 | 4 |
| Completed | 8 | 11 | 4 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participants, in particular, the number of participants with at least one TEAE. Please refer to the detailed tables included on the Adverse Event Module for specifics.
| Participants | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 6 | 7 | 3 |
Summary of the values by visit from baseline and changes from baseline by post-baseline visit.
| millimeters of mercury (mmHg) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| SBP Baseline | 114.2 ± 11.62 | 114.7 ± 13.88 | 114.8 ± 12.97 |
| SBP Week 1 | 115.0 ± 8.35 | 116.7 ± 10.65 | 104.0 ± 8.98 |
| SBP Change from Baseline to Week 1 | 0.8 ± 8.94 | 2.0 ± 9.72 | -10.8 ± 10.90 |
| SBP Week 2 | 113.9 ± 9.41 | 118.3 ± 14.85 | 114.8 ± 15.06 |
| SBP Change from Baseline to Week 2 | -0.3 ± 6.60 | 3.6 ± 8.78 | 0.0 ± 2.83 |
| SBP Week 4 | 112.0 ± 11.20 | 113.9 ± 12.41 | 104.8 ± 6.85 |
| SBP Change from Baseline to Week 4 | -2.2 ± 8.77 | -0.8 ± 8.51 | -10.0 ± 14.72 |
| SBP Week 8 | 114.9 ± 7.41 | 113.8 ± 10.54 | 109.8 ± 12.61 |
| SBP Change from Baseline to Week 8 | 0.7 ± 11.11 | 0.9 ± 9.63 | -5.0 ± 1.63 |
| SBP Week 12 | 113.4 ± 11.02 | 112.8 ± 11.31 | 107.5 ± 10.08 |
| SBP Change from Baseline to Week 12 | -0.8 ± 13.02 | -0.1 ± 10.85 | -7.3 ± 3.40 |
| DBP Baseline | 65.94 ± 10.088 | 65.00 ± 10.189 | 66.50 ± 7.853 |
| DBP Week 1 | 66.44 ± 6.710 | 69.33 ± 9.921 | 61.75 ± 4.856 |
| DBP Change from Baseline to Week 1 | 0.50 ± 4.886 | 4.33 ± 6.344 | -4.75 ± 6.185 |
| DBP Week 2 | 65.89 ± 9.545 | 68.83 ± 11.535 | 64.00 ± 6.055 |
| DBP Change from Baseline to Week 2 | -0.06 ± 5.353 | 3.83 ± 8.726 | -2.50 ± 3.000 |
| DBP Week 4 | 65.22 ± 11.043 | 62.33 ± 9.069 | 62.75 ± 3.775 |
| DBP Change from Baseline to Week 4 | -0.72 ± 9.398 | -2.67 ± 9.921 | -3.75 ± 5.058 |
| DBP Week 8 | 63.44 ± 6.579 | 67.18 ± 9.174 | 66.75 ± 7.500 |
| DBP Change from Baseline to Week 8 | -2.50 ± 8.216 | 3.27 ± 8.439 | 0.25 ± 7.848 |
| DBP Week 12 | 63.67 ± 7.697 | 67.64 ± 9.657 | 62.50 ± 3.317 |
| DBP Change from Baseline to Week 12 | -2.28 ± 10.140 | 3.73 ± 6.310 | -4.00 ± 6.880 |
Summary of the values by visit from baseline and changes from baseline by post-baseline visit.
| Pulse Rate (bpm) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Baseline | 82.00 ± 12.135 | 77.71 ± 10.208 | 73.75 ± 5.560 |
| Week 1 | 82.33 ± 11.694 | 80.33 ± 9.875 | 70.75 ± 6.449 |
| Change from Baseline to Week 1 | 0.33 ± 6.042 | 2.63 ± 5.859 | -3.00 ± 5.715 |
| Week 2 | 83.56 ± 12.856 | 75.83 ± 9.953 | 75.00 ± 8.756 |
| Change from Baseline to Week 2 | 1.56 ± 10.442 | -1.88 ± 8.263 | 1.25 ± 3.775 |
| Week 4 | 82.33 ± 14.414 | 77.92 ± 9.830 | 73.25 ± 3.775 |
| Change from Baseline to Week 4 | 0.33 ± 8.818 | 0.21 ± 5.541 | -0.50 ± 1.915 |
| Week 8 | 83.22 ± 11.322 | 80.27 ± 10.992 | 72.50 ± 5.196 |
| Change from Baseline to Week 8 | 1.22 ± 6.648 | 2.68 ± 9.040 | -1.25 ± 7.411 |
| Week 12 | 81.44 ± 9.002 | 79.91 ± 8.734 | 74.25 ± 4.193 |
| Change from Baseline to Week 12 | -0.56 ± 8.719 | 2.32 ± 9.419 | 0.50 ± 6.137 |
Values by visit from baseline and changes from baseline by post-baseline visit. The following ECG parameters were recorded: PR interval, QRS duration, QT interval, RR interval and QTcF interval. PR interval represents the time from the onset of the P wave to the start of the QRS complex. QRS duration represents the time required for a stimulus to spread through the ventricles (ventricular depolarization). QT interval represents the time from the start of the Q wave to the end of the T wave. RR interval represents the time from the onset of one R wave to the onset of the next one, one complete cardiac cycle. QT corrected for heart rate (QTc) interval reflects ventricular repolarization.
| milliseconds (ms) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| PR interval - Baseline | 158.3 ± 25.14 | 147.6 ± 20.05 | 175.8 ± 38.92 |
| PR interval - Baseline 2h post-dose | 161.2 ± 21.28 | 155.1 ± 17.98 | 175.0 ± 14.07 |
| PR interval - Change from Baseline to Baseline 2h post-dose | 2.9 ± 25.78 | 6.3 ± 16.45 | -0.8 ± 38.59 |
| PR interval - Week 1 | 159.2 ± 22.90 | 153.0 ± 14.12 | 189.5 ± 18.72 |
| PR interval - Change from Baseline to Week 1 | 0.9 ± 16.59 | 4.7 ± 12.71 | 13.8 ± 25.67 |
| PR interval - Week 2 | 167.6 ± 26.49 | 153.0 ± 17.87 | 185.5 ± 4.43 |
| PR interval - Change from Baseline to Week 2 | 9.2 ± 27.64 | 5.5 ± 13.56 | 9.8 ± 37.56 |
| PR interval - Week 4 | 154.0 ± 26.49 | 154.2 ± 21.19 | 185.0 ± 7.39 |
| PR interval - Change from Baseline to Week 4 | -4.3 ± 18.85 | 8.1 ± 15.48 | 9.3 ± 33.42 |
| PR interval - Week 8 | 161.2 ± 19.34 | 153.5 ± 20.61 | 185.8 ± 10.14 |
| PR interval - Change from Baseline to Week 8 | 2.9 ± 17.05 | 7.1 ± 12.66 | 10.0 ± 32.86 |
| PR interval - Week 12 | 160.6 ± 19.55 | 156.6 ± 14.47 | 182.8 ± 11.98 |
| PR interval - Change from Baseline to Week 12 | 2.2 ± 19.50 | 11.5 ± 14.25 | 7.0 ± 36.09 |
| QRS duration - Baseline | 94.0 ± 18.73 | 88.8 ± 19.17 | 119.3 ± 50.12 |
| QRS duration - Baseline 2h post-dose | 94.3 ± 20.21 | 95.8 ± 10.96 | 85.0 ± 11.60 |
| QRS duration - Change from Baseline to Baseline 2h post-dose | 0.3 ± 4.82 | 7.0 ± 14.39 | -34.3 ± 55.27 |
| QRS duration - Week 1 | 98.4 ± 23.16 | 96.1 ± 11.27 | 98.0 ± 16.57 |
| QRS duration - Change from Baseline to Week 1 | 4.4 ± 14.75 | 7.3 ± 13.45 | -21.3 ± 65.76 |
| QRS duration - Week 2 | 94.0 ± 29.01 | 96.3 ± 14.13 | 91.3 ± 12.09 |
| QRS duration - Change from Baseline to Week 2 | 0.0 ± 23.04 | 7.6 ± 17.96 | -28.0 ± 61.36 |
| QRS duration - Week 4 | 92.3 ± 23.32 | 92.6 ± 15.11 | 94.3 ± 8.10 |
| QRS duration - Change from Baseline to Week 4 | -1.7 ± 11.16 | 6.0 ± 16.76 | -25.0 ± 54.02 |
| QRS duration - Week 8 | 91.0 ± 24.72 | 94.9 ± 18.27 | 93.3 ± 10.81 |
| QRS duration - Change from Baseline to Week 8 | -3.0 ± 15.99 | 7.4 ± 28.52 | -26.0 ± 60.02 |
| QRS duration - Week 12 | 94.3 ± 27.31 | 84.8 ± 18.66 | 91.8 ± 10.59 |
| QRS duration - Change from Baseline to Week 12 | 0.3 ± 20.64 | -2.7 ± 23.70 | -27.5 ± 60.69 |
| QT interval - Baseline | 371.7 ± 76.41 | 374.2 ± 21.78 | 420.8 ± 48.75 |
| QT interval - Baseline 2h post-dose | 385.7 ± 50.89 | 376.8 ± 22.25 | 379.5 ± 30.17 |
| QT interval - Change from Baseline to Baseline 2h post-dose | 14.0 ± 61.00 | 2.6 ± 21.49 | -41.3 ± 68.30 |
| QT interval - Week 1 | 394.1 ± 47.36 | 374.8 ± 33.12 | 381.5 ± 32.18 |
| QT interval - Change from Baseline to Week 1 | 22.4 ± 57.20 | 0.7 ± 28.96 | -39.3 ± 71.63 |
| QT interval - Week 2 | 384.0 ± 55.52 | 367.0 ± 24.68 | 378.3 ± 27.89 |
| QT interval - Change from Baseline to Week 2 | 12.3 ± 76.14 | -7.2 ± 27.61 | -42.5 ± 61.87 |
| QT interval - Week 4 | 370.1 ± 67.13 | 373.6 ± 21.22 | 378.0 ± 36.51 |
| QT interval - Change from Baseline to Week 4 | -1.6 ± 23.07 | 0.9 ± 24.94 | -42.8 ± 61.50 |
| QT interval - Week 8 | 389.7 ± 39.20 | 379.4 ± 25.08 | 381.8 ± 37.99 |
| QT interval - Change from Baseline to Week 8 | 18.0 ± 69.60 | 4.6 ± 22.59 | -39.0 ± 64.59 |
| QT interval - Week 12 | 380.9 ± 59.97 | 364.2 ± 36.22 | 388.3 ± 42.85 |
| QT interval - Change from Baseline to Week 12 | 9.2 ± 33.53 | -10.5 ± 33.69 | -32.5 ± 72.06 |
| RR interval - Baseline | 789.4 ± 128.89 | 801.4 ± 95.56 | 877.5 ± 114.65 |
| RR interval - Baseline 2h post-dose | 781.2 ± 155.21 | 805.5 ± 119.36 | 812.5 ± 124.38 |
| RR interval - Change from Baseline to Baseline 2h post-dose | -8.2 ± 87.78 | 4.1 ± 112.91 | -65.0 ± 196.09 |
| RR interval - Week 1 | 793.2 ± 105.35 | 864.9 ± 149.33 | 826.5 ± 96.57 |
| RR interval - Change from Baseline to Week 1 | 3.8 ± 82.82 | 63.5 ± 137.59 | -51.0 ± 98.80 |
| RR interval - Week 2 | 757.3 ± 120.25 | 830.1 ± 138.34 | 833.8 ± 16.01 |
| RR interval - Change from Baseline to Week 2 | -32.1 ± 146.70 | 28.7 ± 117.34 | -43.8 ± 103.92 |
| RR interval - Week 4 | 783.7 ± 110.55 | 829.8 ± 154.72 | 825.8 ± 96.08 |
| RR interval - Change from Baseline to Week 4 | -5.8 ± 62.11 | 34.1 ± 137.64 | -51.8 ± 111.05 |
| RR interval - Week 8 | 765.0 ± 91.52 | 810.1 ± 138.16 | 844.8 ± 135.47 |
| RR interval - Change from Baseline to Week 8 | -24.4 ± 116.42 | 17.2 ± 108.39 | -32.8 ± 152.45 |
| RR interval - Week 12 | 780.7 ± 140.88 | 812.9 ± 93.89 | 878.3 ± 133.70 |
| RR interval - Change from Baseline to Week 12 | -8.8 ± 115.95 | 20.0 ± 73.46 | 0.8 ± 172.81 |
| QTcF interval - Baseline | 403.3 ± 80.48 | 400.5 ± 22.76 | 416.8 ± 17.46 |
| QTcF interval - Baseline 2h post-dose | 419.3 ± 36.58 | 410.1 ± 25.34 | 407.3 ± 13.05 |
| QTcF interval - Change from Baseline to Baseline 2h post-dose | 16.0 ± 66.51 | 9.6 ± 22.60 | -9.5 ± 6.76 |
| QTcF interval - Week 1 | 425.7 ± 37.25 | 397.3 ± 30.44 | 406.8 ± 26.02 |
| QTcF interval - Change from Baseline to Week 1 | 22.3 ± 65.53 | -3.3 ± 24.92 | -10.0 ± 20.38 |
| QTcF interval - Week 2 | 420.8 ± 42.28 | 393.3 ± 28.90 | 402.0 ± 30.30 |
| QTcF interval - Change from Baseline to Week 2 | 17.4 ± 77.84 | -7.2 ± 27.52 | -14.8 ± 14.52 |
| QTcF interval - Week 4 | 401.3 ± 64.21 | 401.8 ± 27.41 | 402.8 ± 23.63 |
| QTcF interval - Change from Baseline to Week 4 | -2.0 ± 24.74 | 2.1 ± 24.41 | -14.0 ± 7.07 |
| QTcF interval - Week 8 | 426.0 ± 30.12 | 399.6 ± 27.17 | 404.3 ± 19.86 |
| QTcF interval - Change from Baseline to Week 8 | 22.7 ± 80.36 | 0.3 ± 26.86 | -12.5 ± 4.51 |
| QTcF interval - Week 12 | 414.1 ± 53.40 | 391.4 ± 42.91 | 405.3 ± 25.71 |
| QTcF interval - Change from Baseline to Week 12 | 10.8 ± 37.94 | -8.0 ± 37.96 | -11.5 ± 10.63 |
Assessment of total serum Iron from baseline over a 12-week period (absolute and change from baseline). For the serum iron parameter, the 'Baseline' was collected during the screening period within the biochemistry sample.
| Micromoles per Litre (umol/L) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Baseline | 23.81 ± 13.438 | 28.42 ± 9.796 | 30.88 ± 13.329 |
| Week 1 | 12.54 ± 9.159 | 11.38 ± 7.693 | 28.20 ± 17.919 |
| Change from Baselines to Week 1 | -11.27 ± 7.158 | -17.03 ± 9.611 | -2.68 ± 12.365 |
| Week 2 | 11.71 ± 8.622 | 12.99 ± 8.978 | 32.48 ± 15.541 |
| Change from Baseline to Week 2 | -9.74 ± 4.707 | -15.43 ± 12.784 | 1.60 ± 3.996 |
| Week 4 | 13.90 ± 12.222 | 12.85 ± 7.583 | 31.08 ± 13.721 |
| Change from Baseline to Week 4 | -9.33 ± 4.659 | -14.03 ± 8.432 | 0.20 ± 2.902 |
| Week 8 | 11.35 ± 7.822 | 11.55 ± 9.651 | 26.70 ± 12.040 |
| Change from Baseline to Week 8 | -11.88 ± 9.627 | -17.05 ± 11.936 | -0.37 ± 3.550 |
| Week 12 | 13.72 ± 11.031 | 11.62 ± 6.442 | 27.10 ± 12.856 |
| Change from Baseline to Week 12 | -10.54 ± 6.782 | -16.22 ± 10.892 | 0.03 ± 2.701 |
Assessment of serum ferritin from baseline over a 12-week period (absolute and change from baseline). For the serum ferritin parameter, the 'Baseline' was collected during the screening period within the biochemistry sample.
| Microgrammes per Litre (ug/L) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Baseline | 403.14 ± 226.315 | 1133.23 ± 2119.115 | 440.03 ± 321.453 |
| Week 1 | 416.76 ± 220.567 | 471.53 ± 209.800 | 445.80 ± 228.244 |
| Change from Baseline to Week 1 | -10.14 ± 31.509 | 40.89 ± 164.466 | 5.77 ± 93.946 |
| Week 2 | 441.34 ± 269.599 | 500.79 ± 230.076 | 411.35 ± 207.477 |
| Change from Baseline to Week 2 | 3.29 ± 60.579 | 23.80 ± 149.147 | -49.80 ± 76.867 |
| Week 4 | 476.60 ± 282.457 | 585.71 ± 311.224 | 389.83 ± 240.553 |
| Change from Baseline to Week 4 | 1.05 ± 61.638 | 89.98 ± 249.397 | -50.20 ± 80.958 |
| Week 8 | 463.67 ± 206.646 | 508.56 ± 211.366 | 340.23 ± 165.356 |
| Change from Baseline to Week 8 | -11.88 ± 43.063 | 52.84 ± 157.952 | -9.45 ± 20.577 |
| Week 12 | 465.72 ± 227.378 | 927.42 ± 1478.471 | 261.70 ± 53.033 |
| Change from Baseline to Week 12 | -15.84 ± 66.208 | -139.23 ± 626.380 | 7.25 ± 57.205 |
Assessment of serum transferrin from baseline over a 12-week period (absolute and change from baseline). For the serum transferrin parameter, the "Baseline 2h post-dose" was defined as the value at Visit 3 2h post-dose.
| Grammes per Litre (g/L) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Baseline 2h post-dose | 1.601 ± 0.4377 | 1.673 ± 0.3177 | 1.655 ± 0.3003 |
| Week 1 | 1.610 ± 0.4557 | 1.822 ± 0.3903 | 1.683 ± 0.2210 |
| Change from Baseline to Week 1 | 0.009 ± 0.1184 | 0.149 ± 0.1334 | 0.028 ± 0.2419 |
| Week 2 | 1.601 ± 0.5043 | 1.759 ± 0.3569 | 1.655 ± 0.2408 |
| Change from Baseline to Week 2 | -0.014 ± 0.1516 | 0.087 ± 0.1429 | 0.000 ± 0.1846 |
| Week 4 | 1.708 ± 0.2672 | 1.705 ± 0.3496 | 1.745 ± 0.3756 |
| Change from Baseline to Week 4 | 0.053 ± 0.2014 | 0.054 ± 0.1535 | 0.090 ± 0.2740 |
| Week 8 | 1.640 ± 0.2745 | 1.725 ± 0.3194 | 1.553 ± 0.2836 |
| Change from Baseline to Week 8 | -0.015 ± 0.0675 | 0.093 ± 0.1618 | -0.120 ± 0.0854 |
| Week 12 | 1.706 ± 0.1954 | 1.656 ± 0.2974 | 1.610 ± 0.4784 |
| Change from Baseline to Week 12 | -0.040 ± 0.1116 | 0.100 ± 0.1044 | -0.063 ± 0.1266 |
Assessment of TSAT from baseline over a 12-week period (absolute and change from baseline). For the calculated transferrin saturation parameter, the 'Baseline' was collected during the screening period within the biochemistry sample. Transferrin Saturation (TSAT) was calculated as Total Iron /Total Iron Binding Capacity (TIBC) X 100.
| TSAT Percentage (%) | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| Baseline | 69.3 ± 31.16 | 79.0 ± 24.05 | 83.3 ± 33.50 |
| Week 1 | 36.8 ± 24.44 | 32.2 ± 21.44 | 56.5 ± 30.56 |
| Change from Baselone to Week 1 | -32.6 ± 19.55 | -46.8 ± 22.55 | -26.8 ± 28.77 |
| Week 2 | 36.0 ± 22.81 | 35.8 ± 24.13 | 71.5 ± 33.91 |
| Change from Baseline to Week 2 | -29.5 ± 14.57 | -43.2 ± 33.23 | -11.8 ± 23.50 |
| Week 4 | 41.0 ± 32.27 | 38.4 ± 24.85 | 82.5 ± 35.00 |
| Change from Baseline to Week 4 | -24.0 ± 18.21 | -38.7 ± 27.57 | -0.8 ± 1.50 |
| Week 8 | 32.3 ± 17.48 | 33.5 ± 27.08 | 77.3 ± 39.26 |
| Change from Baseline to Week 8 | -32.7 ± 25.80 | -47.9 ± 29.70 | -0.3 ± 0.58 |
| Week 12 | 36.0 ± 25.93 | 34.8 ± 17.76 | 76.3 ± 40.99 |
| Change from Baseline to Week 12 | -27.6 ± 20.37 | -46.8 ± 23.61 | -1.3 ± 2.31 |
Sparse sampling for determination of VIT-2763 plasma concentration following multiple dosing was obtained from pre-dose trough to 3 hours or 4 hours post-dose at selected study visits. Pharmacokinetics parameters (Cmax, clearance, distribution volume, area under the curve (AUC) were not calculated for the study.
| nanograms per milliliter (ng/mL) | VIT-2763 QD | VIT-2763 BID |
|---|---|---|
| Visit 3 1 hour post-dose | 796.5 ± 508.2 | 609.6 ± 455.2 |
| Visit 3 4 hours post-dose | 222.3 ± 73.1 | 411.0 ± 269.5 |
| Visit 6 pre-dose | 17.2 ± 10.2 | 114.4 ± 78.2 |
| Visit 6 1 hour post-dose | 986.2 ± 796.7 | 483.5 ± 247.3 |
| Visit 6 3 hours post-dose | 578.2 ± 494.5 | 544.3 ± 337.5 |
| Visit 7 pre-dose | 15.5 ± 6.6 | 111.0 ± 61.9 |
| Visit 7 1 hour post-dose | 751.7 ± 682.3 | 692.2 ± 470.2 |
| Visit 7 4 hours post-dose | 295.5 ± 209.5 | 384.3 ± 200.9 |
| Visit 8 pre-dose | 361.5 ± 579.2 | 136.0 ± 76.8 |
| Visit 8 1 hour post-dose | 894.1 ± 670.3 | 650.6 ± 474.5 |
| Visit 8 3 hours post-dose | 684.0 ± 405.5 | 569.9 ± 343.1 |
Collected over up to 20 weeks (all visits/phone calls through study completion are considered). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VIT-2763 QD | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| VIT-2763 BID | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Placebo | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | VIT-2763 QD | VIT-2763 BID | Placebo |
|---|---|---|---|
| HypoacusisEar and labyrinth disorders | 0/9 | 0/12 | 1/4 |
| Non-cardiac chest painGeneral disorders | 0/9 | 0/12 | 1/4 |
| HeadacheNervous system disorders | 0/9 | 1/12 | 1/4 |
| Respiratory symptomRespiratory, thoracic and mediastinal disorders | 0/9 | 0/12 | 1/4 |
| PruritusSkin and subcutaneous tissue disorders | 0/9 | 0/12 | 1/4 |
| FatigueGeneral disorders | 2/9 | 2/12 | 0/4 |
| DyspepsiaGastrointestinal disorders | 0/9 | 2/12 | 0/4 |
| PyrexiaGeneral disorders | 0/9 | 2/12 | 0/4 |
| AnaemiaBlood and lymphatic system disorders | 1/9 | 1/12 | 0/4 |
| HaemolysisBlood and lymphatic system disorders | 1/9 | 0/12 | 0/4 |
| Age, Categorical(Participants) | VIT-2763 QD | VIT-2763 BID | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 12 | 4 | 25 |
| >=65 years | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | VIT-2763 QD | VIT-2763 BID | Placebo | Total |
|---|---|---|---|---|
| Female | 6 | 2 | 1 | 9 |
| Male | 3 | 10 | 3 | 16 |
| Ethnicity (NIH/OMB)(Participants) | VIT-2763 QD | VIT-2763 BID | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 11 | 4 | 24 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | VIT-2763 QD | VIT-2763 BID | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 3 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 4 | 9 | 3 | 16 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | VIT-2763 QD | VIT-2763 BID | Placebo | Total |
|---|---|---|---|---|
| Greece | 3 | 3 | 1 | 7 |
| Lebanon | 1 | 2 | 0 | 3 |
| Italy | 0 | 3 | 0 | 3 |
| Israel | 0 | 1 | 2 | 3 |
| Thailand | 5 | 3 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2020 to primary completion in Oct 2021, 16 months.
Results were first posted in Dec 2023, 2 years 2 months after primary completion.
Of 29 phase 2 interventional studies under beta-Thalassemia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VIT-2763